Interrupting the FGF19-FGFR4 axis to therapeutically disrupt cancer progression.

Interrupting the FGF19-FGFR4 axis to therapeutically disrupt cancer progression.

Curr Cancer Drug Targets. 2018 Mar 18;:

Authors: Lang L, Shull AY, Teng Y

Abstract
Coordination between amplification of the fibroblast growth factor FGF19, overexpression of its corresponding receptor FGFR4, and hyperactivation of the downstream transmembrane enzyme β-klotho have been found to play pivotal roles in mediating tumor development and progression. Aberrant FGF19-FGFR4 signaling has been implicated in driving specific tumorigenic events including cancer cell proliferation, apoptosis resistance, and metastasis by activating a myriad of downstream signaling cascades. As an attractive target, several strategies implemented to disrupt the FGF19-FGFR4 axis have been developed in recent years, and FGF19-FGFR4 binding inhibitors are being intensely evaluated for their clinical use in treating FGF19-FGFR4 implicated cancers. Based on established work, this review aims to detail how the FGF19-FGFR4 signaling pathway plays a vital role in cancer progression and why disrupting communication between FGF19 and FGFR4 serves as a promising therapeutic strategy for disrupting cancer progression.

PMID: 29557750 [PubMed - as supplied by publisher]

http://ift.tt/2FTHuHe